Earnings Releases·Nov 4, 2026, 4:09 PM ET

PacBio — Third Quarter 2026 Earnings Summary

Total revenue rose 6% year-over-year to $40.6 million, driven by a 17% increase in instrument revenue to $13.2 million, while consumable revenue declined 2% to $20.8 million; GAAP net loss narrowed slightly to $37.8 million from $38.0 million, with non-GAAP net loss improving to $32.8 million from $36.8 million.
Full-year 2026 revenue guidance was raised to a range of $155 million to $160 million, reflecting continued demand for instruments and the adoption of SPRQ-Nx, which accounted for over half of Revio consumable revenue by quarter-end.
Management executed a leadership transition with Jim Gibson stepping down as CFO, Mark Van Oene appointed interim CFO, and Bill Meyer named Chief Accounting Officer while a search for a permanent CFO continues.
Strategic partnerships expanded with GeneDx, the Department of Veterans Affairs, Verily Health, and TychoBio to enhance long-read sequencing capabilities in clinical, research, and AI model training applications, while Vega system placements increased 9% year-over-year to 35 units.